Los Angeles, CA (July 30, 2014) With the advent of non-surgical modalities, stimulation of the brain has become a popular science and researchers must work to ensure systematic methods for consistent results in the study of stroke rehabilitation. A new study out today in The Neuroscientist discusses a systematic shift in perspective and suggests that chronically stimulating premotor areas (PMAs) of the brain would strongly promote stroke motor recovery, for example by restoring balance between the stroke and the intact hemispheres while establishing greater widespread connectivity.
"Before therapeutic potential of brain stimulation is missed amidst the enthusiasm for its ability to augment brain activity, it is urgent to systematically understand whom stimulation of the brain may benefit, how, and why," said study author Dr. Ela Plow from the Biomedical Engineering, Lerner Research Instt. at the Cleveland Clinic Foundation. "Addressing the challenge first in stroke is critical, not just because stroke is the leading cause of long-term adult disability, but also because the field was one of the first to report on therapeutic potential of brain stimulation, but unfortunately the first to witness some of its most noted conflicts as well."
Using a conceptual model, researchers Ela B. Plow, David A. Cunningham, Nicole Varnerin, and Andre Machado suggest expanding the scope of stimulation to include other substrates, such as premotor and supplementary motor cortices that are more likely to survive damage in humans, offer their independent output, and collaborate with areas in the intact hemisphere to recruit their cooperation towards recovery as well. Rather than propose that these substrates could serve as the be-all-end-all of plasticity, the researchers suggest that their role may be more meaningful in those with greater damage and do not discount the possibility of success for other substrates such as cerebellum, striatum, parietal cortices etc.
Dr. Plow continued, "Conflicting evidence in stroke has dampened the enthusiasm for brain stimulation witnessed across several hundred early studies in the last decade, limiting the potential of clinical outpatient or even inpatient delivery in the immediate future. Before starting another clinical trial and waiting to see if by chance the new study shows positive effects, we suggest re-evaluating and shifting perspective."
The researchers outline the journey of stimulation in stroke rehabilitation from trials with homogeneous animal models, to early clinical studies where patients with greater sparing of motor cortices and spared output responded exceptionally well to stimulation of their residual cortex, to larger clinical trials that enrolled the more impaired such as those with greater damage to cortices, in which stimulation of motor cortices failed to uniformly augment outcomes of recovery.
With such differences among trial groups, the researchers found that a great discordance between early and later, larger clinical studies resulted. Dr. Plow commented, "By following a one-size-fits-all approach, we risk relying only on pure chance."
However, the researchers also found that this can be corrected with new thinking for brain stimulation research.
"Our intent here is to create a shift in perspective that forces us to broaden scope of stimulation from affecting a single target and a single mechanism to imagining how and what may remain to assume the potential for recovery in humans," Dr. Plow continued. "We even suggest that targets may not even need to be uniform across all, because it may leave outcomes of trials to pure chance. Instead, we believe systematically exploring substrates and defining successes and failures of each would truly create personalized, not popular science."
Read the full article, "Rethinking stimulation of brain in stroke rehabilitation: Why higher-motor areas might be better alternatives for patients with greater impairments," in The Neuroscientist, free for a limited time here: http://ow.ly/zi6ui.
Edited by Stephen G. Waxman of Yale University School of Medicine with help from a renowned international editorial board that includes Nobel Prize winners and experts from top universities from around the world, The Neuroscientist reviews and evaluates the noteworthy advances and key trends in molecular, cellular, developmental, behavioral/systems, and cognitive neuroscience in a unique disease-relevant format. http://nro.sagepub.com/
SAGE is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology, and medicine. An independent company, SAGE has principal offices in Los Angeles, London, New Delhi, Singapore and Washington DC. http://www.sagepublications.com